Reuters logo
BRIEF-Ra Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of RA101495 SC
December 4, 2017 / 12:13 PM / 13 days ago

BRIEF-Ra Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of RA101495 SC

Dec 4 (Reuters) - Ra Pharmaceuticals Inc:

* RA PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF RA101495 SC IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

* RA PHARMACEUTICALS INC - RA101495 SC MET PRIMARY ENDPOINT IN ECULIZUMAB NAÏVE PATIENTS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below